Market Overview - The Hong Kong stock market opened mixed on September 25, with the Hang Seng Index rising initially but closing down 0.13% at 26,484.68 points. The Hang Seng Tech Index increased by 0.89% to 6,379.19 points, while the National Enterprises Index rose slightly by 0.01% to 9,444.22 points [1] - The Hang Seng Index reached a high of 26,640.53 points during the day before retreating, with a total turnover exceeding 314.8 billion HKD. The southbound trading (Hong Kong Stock Connect) saw a net inflow of over 11 billion HKD [1] Sector Performance - Most sectors experienced declines, with notable increases in biopharmaceuticals, new energy vehicles, and wind power stocks. Conversely, sectors such as real estate, gold, banking, insurance, brokerage, gas, and coal saw significant declines [1] Individual Stock Movements - Notable stock movements included: - Delin Holdings up 11.65% - Hang Seng Bank down 3.13% - Yimai Sunshine up 14.08% - Huilyang Technology up 4.11% - Goldwind Technology up 5.25% - ZTE Corporation up 4.80% - Cloudtop New Medicine up 4.48% - Zhenjiu Lidu down 4.13% - Jingji Group surged 160.53% - Zijin Mining up 5.13% - Chery Automobile up 3.80% - JD Group up 3.46% - China Everbright Holdings up 25.89% - Yunfeng Financial down 6.60% [1] Top Traded Stocks - The top three traded stocks included: - Alibaba down 1.15% with a turnover exceeding 30 billion HKD - Xiaomi Group up 4.48% with a turnover exceeding 19.3 billion HKD - Tencent Holdings up 0.23% with a turnover exceeding 11.3 billion HKD [2]

恒生港股通创新药指数通过在编制方案中剔除CXO，成为ETF跟踪的指数中首批"纯度"100%的创新药 指数，更加精准地反映我国创新药企的整体表现。目前，恒生创新药ETF（159316）是市场唯一跟踪该 指数的产品，可助力投资者精准布局创新药产业发展机遇。 昨日，恒瑞医药宣布与全球制药公司Glenmark达成独家许可协议，将其自主研发的HER2 ADC药物瑞康 曲妥珠单抗(1811)在除中、美、欧、日等核心市场外的全球权益授权给Glenmark，并收取1800万美元首 付款及最高10.93亿美元的潜在里程碑付款。 有分析认为，恒瑞医药HER2 ADC药物的海外授权交易证明中国创新药企已具备全球竞争力，此次交易 打破了近期创新药板块缺乏BD事件催化的平淡局面，加之即将到来的欧洲肿瘤内科学会及第四季度传 统BD交易高频期，市场对后续BD事件预期升温，有望开启新一轮创新药行情。 港股创新药板块午后维持红盘震荡，截至14:45，恒生港股通创新药指数上涨0.6%，云顶新耀涨超5%， 乐普生物-B涨超3%，康方生物、恒瑞医药等多股涨超1%，此前连续3日"吸金"的恒生创新药ETF （159316）盘中再获2100万份净申购。 ...

Core Viewpoint - Genting Yongying (01952) has seen a significant increase in stock price, attributed to the approval of production expansion for its core product, Naisfankang, and its inclusion in a global kidney disease management guideline, indicating a strategic shift in treatment options for IgA nephropathy patients [1] Group 1: Financial Performance - Genting Yongying's stock rose over 6%, currently up 5.39% at HKD 57.65, with a trading volume of HKD 300 million [1] - Naisfankang's sales revenue reached HKD 520 million in August, with a shipment volume exceeding 100,000 bottles, marking a new monthly high since its launch [1] - The company has raised its revenue guidance for the full year 2025 to HKD 1.2-1.4 billion, with expectations to further increase it to HKD 2.4-2.6 billion in 2026 [1] Group 2: Product Development and Market Position - The production expansion application for Naisfankang was approved by the National Medical Products Administration in early August, allowing the company to resume its sales growth [1] - On September 19, Genting Yongying announced that Naisfankang was included in the 2025 KDIGO Clinical Practice Guidelines for IgA Nephropathy and IgA Vasculitis, becoming the only recommended treatment for IgA nephropathy in the guideline [1] - The inclusion in the KDIGO guidelines is seen as a significant milestone, providing new treatment options for IgA nephropathy patients and indicating a shift in global treatment strategies [1]

Core Viewpoint - CloudTop New Horizon (01952) has seen a significant increase in stock price, rising over 6% in the afternoon trading session, attributed to the approval of production expansion for its core product, Naisukan, and its inclusion in a global kidney disease management guideline [1] Group 1: Financial Performance - Naisukan's sales revenue reached 520 million yuan in August, marking a record high for monthly sales since its launch, with over 100,000 bottles shipped [1] - The company has raised its revenue guidance for the full year 2025 to 1.2-1.4 billion yuan, with expectations to further increase to 2.4-2.6 billion yuan in 2026 [1] Group 2: Regulatory and Market Developments - The production expansion application for Naisukan was approved by the National Medical Products Administration in early August, allowing the company to resume its sales growth [1] - On September 19, Naisukan was included in the 2025 KDIGO Clinical Practice Guidelines for IgA Nephropathy and IgA Vasculitis, becoming the only recommended treatment for IgA nephropathy in the guideline, indicating a shift in global treatment strategies [1]

Group 1 - The A-share pharmaceutical sector showed recovery with significant gains in innovative drugs and traditional Chinese medicine, highlighted by Ganli Pharmaceutical's strong performance and a supply agreement worth no less than 3 billion yuan with a Brazilian company [1] - The largest medical ETF in A-shares saw a rebound, with notable increases in CXO concept stocks and medical consumables, indicating a recovery in the medical sector [3] - The Hong Kong stock market displayed mixed performance in innovative drugs, with some leading stocks rising while others fell, reflecting a volatile market environment [5] Group 2 - The fund manager of the Hong Kong Innovation Drug ETF expressed optimism about the CXO sector and the potential for a mid-term rotation towards large-cap blue-chip companies, while cautioning about the performance of small-cap companies [6] - The medical ETF market is dominated by the medical ETF (512170) with a scale of 26.5 billion yuan, making it the largest in the sector, while the drug ETF is the only one tracking the CSI Pharmaceutical Index [8] - The Hong Kong Innovation Drug ETF is designed to passively track the Hang Seng Hong Kong Innovation Drug Select Index, which has shown negative annual returns since its inception, indicating potential challenges ahead [9]

美联储于9月18日如期宣布降息25bp，为港股市场提供了较为宽松的流动性环境。但当前距离10月29日 议息尚有35天，美联储相关官员的发言在短期内引起较大扰动。 展望后市，市场预期年内还将有两次降息。据CME FedWatch Tool数据，美联储10月降息25bp的概率为 91.9%；12月降息25bp的概率为21.7%，降息50bp的概率为77%。 每日经济新闻 中邮证券表示，创新药当前处于相对高位，震荡在所难免，需要把握真正优质创新资产；国内创新药景 气度基本见底，后续研发需求有望兑现到CRO行业业绩。 从二级市场来看，聚焦港股市场创新药+CXO的恒生医药ETF（159892）连续调整，自阶段高点回落近 6%。其持仓股映恩生物今日领跌，三生制药、再鼎医药、云顶新耀、亚盛医药等跌幅靠前。 ...

建议关注：①全球大单品：百济神州(06160)，科伦博泰生物(06990)，信达生物(01801)，康方生物 (09926)，三生制药(01530)，百利天恒(688506.SH)，新诺威(300765.SZ)，石药集团(01093)，翰森制药 (03692)，中国生物制药(01177)，一品红(300723.SZ)，映恩生物(09606)； ②全球BIC潜力：益方生物(688382.SH)，泽璟制药(688266.SH)，基石药业(01592)，苑东生物 (688513.SH)，科济药业(02171)，来凯医药(02105)，复宏汉霖(02696)，再鼎医药(09688)，和黄医药 (00013)，药捷安康(02617)，加科思(01167)，歌礼制药(01672)； ③国内大单品：舒泰神(300204.SZ)，艾力斯(688578.SH)，云顶新耀(01952)，恒瑞医药(600276.SH)，贝 达药业(300558.SZ)，华领医药(02552)； ④资产价值：和铂医药(02142)，和誉(02256)。 立足现在：进军全球商业化，大量优质项目将继续推高产业发展 中国创新药行业已形成以领头企业为引领、 ...

Core Insights - The article discusses the recent trends and developments in the pharmaceutical industry, particularly focusing on the performance of innovative drug companies and their clinical trials [5][11][18]. Group 1: Market Performance - The pharmaceutical and biotechnology indices experienced a decline, with the pharmaceutical index dropping by 1.21%, underperforming the Shanghai Composite Index by 0.91 percentage points [5]. - The Hang Seng Healthcare Index fell by 1.55%, and the Hong Kong innovative drug ETF decreased by 1.52% during the same period [5]. Group 2: Company Developments - Xianweida Biotechnology submitted an A1 listing application to the Hong Kong Stock Exchange, with cumulative losses exceeding 1 billion yuan over the past two and a half years [6][7]. - Xianweida's core product, Ecnoglutide, is expected to submit applications for overweight/obesity and type 2 diabetes indications by the end of 2024, with anticipated approval in early 2026 [7][8]. - The company reported no revenue for 2023 and 2024, with losses of 620 million yuan and 486 million yuan, respectively [8]. Group 3: Clinical Trials - Bai Li Tianheng's ADC drug BL-M07D1 has entered a phase III clinical trial for HER2-positive gastric cancer, with a focus on overall survival and progression-free survival as primary endpoints [15][16]. - The SLIMMER study, a significant phase III trial for Ecnoglutide, showed that participants could lose up to 13.8 kg over 48 weeks, with minimal weight regain after stopping the treatment [7]. Group 4: Stock Market Dynamics - The stock of Yaojie Ankang-B experienced extreme volatility, with a price drop from 679.5 HKD to 192 HKD per share, reflecting the high-risk nature of the Hong Kong market for uncommercialized biotech firms [12][13]. - The market's reaction to Yaojie Ankang-B's inclusion in the Hong Kong Stock Connect innovative drug index raised concerns about the decision-making process for including emerging companies in such indices [13]. Group 5: Regulatory Recognition - Yunding Xinyao's core product, Budesonide enteric-coated capsules, has been included in the global kidney disease guidelines, marking it as the only recommended treatment for IgA nephropathy [18].

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing increased volatility, with significant inflows of capital into the high-elasticity Hong Kong Stock Connect innovative drug ETF (520880) and a notable performance from key constituent stocks [1][3]. Group 1: Market Performance - On September 22, the Hong Kong Stock Connect innovative drug sector opened high and continued to rise, with the ETF (520880) reaching an intraday increase of 2.57% and a trading volume exceeding 1 billion CNY [1]. - As of September 19, the ETF (520880) has attracted nearly 680 million CNY over 14 consecutive days [1]. - The ETF's index has shown a year-to-date increase of 119.75% prior to the recent "purification" adjustment on September 8, leading among similar innovative drug indices [4][5]. Group 2: Key Stocks and Trends - Notable performers among the ETF's constituent stocks include MIRXES-B, Kangnuo Ya-B, and Heng Rui Pharmaceutical, with respective increases of over 6.7%, 6%, and 4.6% [1]. - Conversely, Junshi Biosciences and Sihuan Pharmaceutical have shown negative performance [1]. Group 3: Industry Insights - According to Huachuang Securities, the innovative drug industry is transitioning from a quantity-driven logic to a quality-driven logic, with 2025 expected to be a pivotal year focused on product excellence [3]. - Southwest Securities reported that in the first half of 2025, the revenue for the Hong Kong Stock Connect innovative drug sector is projected to be 194.6 billion CNY, a decrease of 2.0%, while net profit is expected to rise by 1.2% to 25.8 billion CNY [3]. - The innovative drug pipeline in China has reached 3,575 molecules, ranking first globally, with 18 original drugs already launched overseas [2]. Group 4: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) is the first ETF tracking the Hang Seng Stock Connect Innovative Drug Select Index, with a fund size exceeding 1.7 billion CNY as of September 12 [5]. - The ETF has been restructured to exclude CXO companies, focusing solely on innovative drug research and development, thereby enhancing its representation of the core strength of domestic innovative drugs [3][4].

Core Viewpoint - The innovative drug sector is currently experiencing a phase of adjustment, with significant fluctuations in stock prices and ongoing capital inflows into the market [1][3][5]. Group 1: Market Performance - On September 19, A-share market saw a decline in innovative drug stocks, with Kanghong Pharmaceutical down 6% and Xinlitai and Kelun Pharmaceutical dropping over 3.8% [1]. - The Hong Kong Stock Connect innovative drug ETF (520880) opened high but closed lower, with a decline of 1.58% and a trading volume of 335 million yuan [1]. - The ETF has seen continuous capital inflow for 13 days, totaling over 670 million yuan as of September 18 [3]. Group 2: Investment Opportunities - Despite short-term volatility, the long-term logic of the innovative drug sector remains intact, with no substantial negative news impacting the market [5]. - The current macroeconomic environment is favorable, with the Federal Reserve restarting its interest rate cut cycle, which may benefit the global pharmaceutical sector [5][6]. - The trend of innovative drugs is clear, with several products entering advanced negotiation stages for overseas markets, potentially leading to continuous cash flow [6]. Group 3: ETF Adjustments - The Hong Kong Stock Connect innovative drug ETF (520880) has undergone a "purification" revision, completely excluding CXO companies and focusing solely on innovative drug R&D firms [6][7]. - As of September 5, the ETF had achieved a year-to-date increase of 119.75%, outperforming other innovative drug indices [7][8]. - The ETF is the first in the market to track the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, with a fund size exceeding 1.7 billion yuan and the highest liquidity among similar products [8].